Cover Image
QR Code

A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.

Biliary tract cancers (BTC) are rare and aggressive tumors with poor prognosis. Radical surgery offers the best chance for cure; however, most patients present with unresectable disease, and among those receiving curative-intent surgery, recurrence rates remain high. While other locoregional therapi...

Full description

Published in:Current Oncology Vol. 30; no. 8; pp. 7132 - 7151
Main Authors: Ramjeesingh, Ravi, Chaudhury, Prosanto, Tam, Vincent C., Roberge, David, Lim, Howard J., Knox, Jennifer J., Asselah, Jamil, Doucette, Sarah, Chhiber, Nirlep, Goodwin, Rachel
Format: Journal Article
Published: MDPI Aug2023
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=170737250&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 170737250
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Aug2023
      vid: 30
      iid: 8
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        170737250
        10.3390/curroncol30080517
        170737250
      ppf: 7132
      ppct: 19
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
      aug:
        au:
          Ramjeesingh, Ravi
          Chaudhury, Prosanto
          Tam, Vincent C.
          Roberge, David
          Lim, Howard J.
          Knox, Jennifer J.
          Asselah, Jamil
          Doucette, Sarah
          Chhiber, Nirlep
          Goodwin, Rachel
        affil: Division of Medical Oncology, Department of Medicine, Nova Scotia Health, Dalhousie University, Halifax, NS B3H 2Y9, Canada
      sug:
      ab: Biliary tract cancers (BTC) are rare and aggressive tumors with poor prognosis. Radical surgery offers the best chance for cure; however, most patients present with unresectable disease, and among those receiving curative-intent surgery, recurrence rates remain high. While other locoregional therapies for unresectable disease may be considered, only select patients may be eligible. Consequently, systemic therapy plays a significant role in the treatment of BTC. In the adjuvant setting, capecitabine is recommended following curative-intent resection. In the neoadjuvant setting, systemic therapy has mostly been explored for downstaging in borderline resectable tumours, although evidence for its routine use is lacking. For advanced unresectable or metastatic disease, gemcitabine-cisplatin plus durvalumab has become the standard of care, while the addition of pembrolizumab to gemcitabine-cisplatin has also recently demonstrated improved survival compared to chemotherapy alone. Following progression on gemcitabine-cisplatin, several chemotherapy combinations and biomarker-driven targeted agents have been explored. However, the optimum regimen remains unclear, and access to targeted agents remains challenging in Canada. Overall, this article serves as a practical guide for the systemic treatment of BTC in Canada, providing valuable insights into the current and future treatment landscape for this challenging disease.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N